Alzheimer's disease (AD), the most common form of dementia, is rapidly becoming a major global health concern among the elderly. Multiple pathogenic components and abnormalities in the behavior of various cell types within the CNS play a role in AD pathogenesis. The most well-studied form of neurodegenerative amyloidopathy is Alzheimer's disease (AD). Molecular pathology, aided by genomes and proteomics, is improving our understanding of neurodegenerative disease development, diagnosis, and treatment. The goal of molecular pathology is to uncover disease mechanisms by identifying molecular and pathway changes. The use of old and novel tools established in biochemistry, cell biology, molecular biology, proteomics, and genetics to the evaluation of pathological processes is at the heart of this still-evolving science. The value of molecular pathology as a supplement to histopathology in nonclinical drug development is well understood in the pharmaceutical industry.
Title : Cerebral vascular calcium signaling in diabetic alzheimer's disease-related dementias
Yong Xiao Wang, Albany Medical College, United States
Title : Development of imaging based biomarkers for neurovascular abnormalities in neurodegenerative diseases
Jun Hua, Johns Hopkins University School of Medicine, United States
Title : Deep learning-based risk assessment of cognitive impairment using health examination data
Kaoru Sakatani, The University of Tokyo, Japan
Title : Him, that person and me
Simon C Barton, Stroke Survivor, United States
Title : Evaluation of the neuroprotective potential of indicaxanthin from opuntia ficus indica fruit against dysmetabolism-related neurodegeneration both in vivo and in vitro
Mario Allegra, University of Palermo, Italy
Title : Psychosocial considerations in management of corticobasal degeneration
Esraa Askar, Forest Hills Hospital, United States